Wilson’s bullish
TELA Bio | 2Q24| Investment ViewTELA Bio (TELA) missed estimates in 2Q24, reporting US$16.1M OviTex revenue (WILSe:US$18.4M) but maintained full year guidance at US$74.5-76.5M. Similar but independent cyber-attacks impacted a national GPO and hospital customer, impacting revenue by ~US$1.5-2.0M.We maintain OVERWEIGHT rating and $1.00 PT on Aroa Biosurgery. Minimal impact to ARX.| Announcement HighlightsAroa’s US channel partner TELA Bio released 2Q24 results. OviTex revenue of US$16.1M was below our forecast (WILSe: US$18.4M) representing11% growth vs pcp. The FY24 revenue guidance range was maintained, noting a recovery in volumes in 3Q. The impacted GPO (Ascension) was arelatively new channel partner and growing quickly. The incident emerged in early May and was resolved within a few weeks. TELA estimates an impactof US$1.25-1.75M from this event. Separately, a large hospital customer
Wilson’s bullishTELA Bio | 2Q24| Investment ViewTELA Bio (TELA)...
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
53.5¢ |
Change
-0.015(2.73%) |
Mkt cap ! $184.5M | |||
| Open | High | Low | Value | Volume |
| 55.0¢ | 55.0¢ | 53.5¢ | $122.9K | 225.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29784 | 53.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.0¢ | 80000 | 1 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| ARX (ASX) Chart |